<DOC>
	<DOCNO>NCT00102661</DOCNO>
	<brief_summary>The goal clinical research study learn give CAMPATH-1H first injection vein , injection skin shrink slow growth disease patient chronic lymphocytic leukemia ( CLL ) already receive standard therapy . Another goal learn side effect related CAMPATH-1H treatment less severe give drug first injection vein injection skin .</brief_summary>
	<brief_title>Continuous Infusion Campath-1H Followed Subcutaneous Injections Previously Treated Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>The purpose trial : 1 . To evaluate response rate ( CR+PR ) CAMPATH-1H give continuous infusion follow subcutaneous injection patient previously treat CLL fail fludarabine therapy . 2 . To evaluate whether CAMPATH-1H , give continuous infusion follow subcutaneous injection patient previously treat CLL improve tolerability agent permit high dos deliver route . 3 . To evaluate pharmacokinetics CAMPATH-1H give 24 hour continuous infusion follow subcutaneous injection .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Age &gt; = 18 year ( CLL occur pediatric population ) . Signed informed consent . World Health Organization ( WHO ) performance status 0 , 1 , 2 . Patients BCLL receive fludarabine either refractory frontline therapy relapse within six month receive fludarabinebased therapy . Patients previously treat Campath1H eligible . Serum creatinine &lt; = 2mg/dL , total bilirubin &lt; = 2mg/dL , SGPT &lt; = 3x upper limit normal ( ULN ) unless due direct infiltration liver kidney malignant cell . Past history anaphylaxis , follow exposure rat mouse derive CDRgrafted humanize monoclonal antibody . Prior chemotherapy , immunotherapy , hormonal therapy within 2 week prior study start . Hormonal replacement therapy permit . Prior therapy monoclonal antibody least 4 week prior study start . Pregnant nursing woman patient childbearing age unwilling practice acceptable form contraception . Patients history HIV positivity . Active secondary malignancy . Active uncontrolled infection major systemic illness would , opinion investigator , interfere patient 's ability comply protocol , compromise patient safety interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>